Bulk Quote Inquiry

SMF-HM407-100μg / Inquiry

SMF-HM407-500μg / Inquiry

SMF-HM407-1mg / Inquiry

Human SLAMF7/CRACC/CD319 Protein

Product Info

Recombinant Human SLAMF7/CRACC/CD319 Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Ser23-Met226[Accession | Q9NQ25]

Molecular Weight

The protein has a predicted MW of 25.3 kDa. Due to glycosylation, the protein migrates to 40-55 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by SEC-HPLC


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5 % trehalose is added as protectant before lyophilization.


Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.


The product should be stored at -70℃ or -20℃.

Assay Data
Tris-Bis PAGE

Human SLAMF7 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.


The purity of Human SLAMF7 is greater than 95% as determined by SEC-HPLC.


Immobilized Human SLAMF7 at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 20.9ng/ml determined by ELISA.


CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family.Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response.


CD319 antigen; CD319; 19A; CD2 subset 1; CD2-like receptor activating cytotoxic cells; CRACC; CRACCCD2-like receptor-activating cytotoxic cells; CS119A24 protein; Membrane protein FOAP-12; novel LY9 (lymphocyte antigen 9) like protein; Novel Ly9; Protein 19A; SLAM family member 7; SLAMF7;CS1


(1)Niels W. C. J. van de Donk, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma[J]. Blood, 2016, 127(6):681-695.

Kactus Biosystems Co.Ltd
Online Message